机译:对癌症癌症患者危重患者的药理学静脉血栓预防的解二分割肝素与低分子量肝素和Fordaparinux的评价
Department of Clinical Pharmacy and Translational ScienceUniversity of Tennessee Health Science;
Department of Clinical PharmacyUniversity of ColoradoAurora CO USA;
Department of Clinical PharmacyUniversity of ColoradoAurora CO USA;
Department of Clinical PharmacyUniversity of ColoradoAurora CO USA;
Department of Clinical PharmacyUniversity of ColoradoAurora CO USA;
Division of Pulmonary Sciences and Critical Care MedicineUniversity of Colorado DenverAurora CO USA;
Division of Pulmonary Sciences and Critical Care MedicineUniversity of Colorado DenverAurora CO USA;
Colorado Pulmonary Outcomes Research Group (CPOR)University of ColoradoAurora;
Division of Pulmonary Sciences and Critical Care MedicineUniversity of Colorado DenverAurora CO USA;
Department of Clinical PharmacyUniversity of ColoradoAurora CO USA;
critical illness; heparin; low‐molecular‐weight; heparin; unfractionated; neoplasms; prophylaxis; venous thromboembolism;
机译:对癌症癌症患者危重患者的药理学静脉血栓预防的解二分割肝素与低分子量肝素和Fordaparinux的评价
机译:创伤性脑损伤中的药理血栓栓塞预防低分子量肝素优于未分割的肝素
机译:与术后结肠直肠患者相关的静脉血栓栓塞栓塞的出血:无分量肝素与低分子量肝素的随机前瞻性研究
机译:静脉血栓形成的治疗; RapidMist快速释放口服低分子量肝素喷雾剂
机译:竞争性风险分析用于评价达肝素与普通肝素对外科手术重症患者静脉血栓栓塞的疗效
机译:对癌症患者癌症患者的药理学静脉血栓预防,对低分量肝素与低分子量肝素和Fordaparinux的评价